Accretion Pharmaceuticals Limited specializes in manufacturing and marketing high-quality generic and branded pharmaceutical formulations. They listed on the NSE Emerge platform in May 2025 and achieved a 40% production capacity increase post-IPO.

The company recorded a remarkable revenue growth of 135.59% in H1 FY '26, driven by a diversified product mix and strategic market expansion.

Accretion focuses on expanding its reach into high-growth markets like Africa, Southeast Asia, and Latin America, leveraging certifications like WHO-cGMP and ISO 9001-2015.

The executive team emphasizes a robust export strategy, with over 100 products under registration across multiple countries, highlighting their aggressive market penetration efforts.